Vineti Completes $33.5 Million in Series B Financing to Accelerate Patient Access to Cell and Gene TherapiesDriven by an industry-leading, multi-disciplinary team, Vineti’s digital platform enables the rapid expansion of transformative cell and gene therapies for cancer and other serious diseases. Series B round led by Canaan and DFJ, along with other top investors. SAN FRANCISCO, April 16, 2018-- Vineti, Inc., the leading software automation and analytics platform for cell and gene therapies, today announced the closing of $33.5 million in Series B investment to support expansion of the company’s technology platform for individualized therapies.